MedPharm opens new £500,000 UK GMP facility

3-Oct-2013

Adds a microbiology lab, cleanroom suites, ICH stability testing area to support clinical trials

MedPharm, a UK-based topical and transdermal formulation development specialist, has opened a new £500,000 GMP facility in Guildford as it strives to double turnover and increase market share over the next five years.

The investment adds a new microbiology laboratory, cleanroom suites, a dedicated ICH stability testing area and a quality control and performance testing laboratories to support Phase I and II clinical manufacture. The facility also allows for the manufacture of highly potent compounds up to OEB 4 level with a manufacturing batch scale of up to 50kg and primary packaging, labelling and randomisation services.

'The opening of the new site is a huge milestone for our business. We can now offer a true one-stop shop for formulation development, all provided in house,' said MedPharm's Chief Executive Dr Andrew Muddle.

'In particular, the bespoke clinical trials supplies production facility, regulated by state-of-the-art monitoring systems, will provide clinical manufacturing capabilities designed to handle a range of non-sterile dosage forms. These include liquids, semi-solid gels, creams and ointments, as well as inhaled products, sprays and transdermal patches.'

Sign up for your free email newsletter

The expansion was funded partly with assistance from Lloyds Commercial Banking.

Companies